| |
 Science
Yasuhiro Hashimoto, M.D.
President & CEO
MediBIC Group
Dr. Hashimoto is a graduate
of Osaka University Medical School. Following his postdoctoral
research at Harvard University Medical School, he became
an Associate Professor and Adjunct Professor at the University
of Pennsylvania. He also experienced Senior Director of
the Institute of Immunology, Syntex, Japan, Director, Biotechnology
Department of Roche (US) and Director of Molecular Biology
Department for the Tsukuba Laboratory of Nippon Glaxo Ltd
(currently GlaxoSmithKline K.K.). During Nippon Glaxo, he
was involved in PGx project planning.
In 2000, he founded MediBIC and is the President
and CEO to this date, serving Board of Director in several
Asian biotech companies, as well. |
Technology
Hiroki Nakae, Ph.D.
Executive Managing Director, MediBIC Group
Executive Vice President, MediBIC
Dr. Nakae was a neuroscientst in Advanced
Research Lab., Toshiba Corp. followed by a bioinformatician
in Life Science Group, Hitachi Ltd. responsible for R&D
and business development and the CEO of Canaledge Inc.
Dr. Nakae joined MediBIC as Managing Director,
Business Operation Division in January 2006.
In March 2007, he was appointed Executive Managing
Director, MediBIC Group. |
Business
Management
| Takeshi Kanda
Executive Vice President,MediBIC Group
Mr.Kanda is the President and CEO of Frontier
Consulting Japan, Inc, which he founded in 2007.His former
experiences include Nikko Cordial Securities Inc and Corporate
Officer,Trans-Science Inc.
He joined MediBIC as an External Director in
March 2008. |
|
John Fou
External Director,MediBIC Group
Mr.Fou is the Co-founder and Representative
Director of Generation Group KK.
Formerly he worked for Baring Securities, and
was Executive Director, Securities Investment, at the Canadian
Imperial Bank of Commerce (CIBC), Director, Equity Trading
at Dresdner Kleinwort Wasserstein Securites,etc.
He joined MediBIC as an External Director in
March 2008.
|
Compliance
| Kazuo Usui, US C.P.A.
Statutory Auditor, MediBIC Group
Mr. Usui has experiences as Financial Manager
and Internal Audits of Chase Manhattan Bank, Advisor of
Nippon Becton Dickinson Co., Ltd, and President & CFO
of Fresenius Medical Care Japan Co. Ltd,
Mr. Usui joined MediBIC as a Statutory Auditor
from March 2006. |
|
Kazuharu Tomioka
Statutory Auditor, MediBIC Group
After working for the IPO department of Daiwa
Securities Co., Ltd, Mr. Tomioka established Disclosure
Inc. and was appointed CEO.
At Daiwa Securities, he made large-scale enlistments with
companies such as NTT DATA CORPORATION and Daini Denden
Inc. (currently KDDI CORPORATION) and enlisted over 50 other
companies.
Mr. Tomioka joined MediBIC in March 2003, and
after his role as Executive Director, he was appointed a
Statutory Auditor in March 2005.
He is also an Auditor for Invoice Inc. |
|
|
Akiyoshi Uchiyama, M.D., Ph.D.
Statutory Auditor, MediBIC Group
Dr. Uchiyama founded Artage, Inc in 2004 and
is the President to this day. He is also Deputy Director,
Development & Medical Affairs Division of GlaxoSmithKline
K. K.
After graduating Hamamatsu University, he joined
the Hamamatsu University Orthopedic Department followed
by a year at Harvard Medical School Orthopedic Research
as a post-doctoral fellow before joining Eisai Co. Ltd.
At GlaxoSmithKline, he is responsible for regulatory affairs,
drug safety, clinical development and compliance.
He joined MediBIC as a Statutory Auditor in
March 2008. |
|
